Last reviewed · How we verify
Amoxicillin Capsules
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking. Used for Bacterial infections caused by susceptible organisms (respiratory tract infections, otitis media, sinusitis, urinary tract infections, skin and soft tissue infections, streptococcal pharyngitis), Helicobacter pylori eradication (as part of combination therapy).
At a glance
| Generic name | Amoxicillin Capsules |
|---|---|
| Also known as | Amoxicillin |
| Sponsor | The Third Xiangya Hospital of Central South University |
| Drug class | Beta-lactam antibiotic (aminopenicillin) |
| Target | Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Amoxicillin is a beta-lactam antibiotic that penetrates bacterial cell walls and irreversibly binds to penicillin-binding proteins (PBPs), preventing the cross-linking of peptidoglycan strands. This disrupts cell wall integrity, leading to bacterial cell lysis and death. It is bactericidal and effective against a broad spectrum of gram-positive and some gram-negative bacteria.
Approved indications
- Bacterial infections caused by susceptible organisms (respiratory tract infections, otitis media, sinusitis, urinary tract infections, skin and soft tissue infections, streptococcal pharyngitis)
- Helicobacter pylori eradication (as part of combination therapy)
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Allergic reaction/anaphylaxis
- Abdominal pain
Key clinical trials
- Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial (NA)
- Effect of Antibiotics on Enteric Neurons and Glia (PHASE4)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication (PHASE3)
- Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1 (PHASE4)
- Drug-Drug Interaction Between DW4421 and Amoxicillin/Clarithromycin (PHASE1)
- Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward (PHASE3)
- The Role of Microbiome in Recurrent Obesity Before and After Antibiotic/Placebo Treatment (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amoxicillin Capsules CI brief — competitive landscape report
- Amoxicillin Capsules updates RSS · CI watch RSS
- The Third Xiangya Hospital of Central South University portfolio CI